Synonyms: CDP870 | Cimzia® | PHA 738144
certolizumab pegol is an approved drug (FDA (2008), EMA (2009))
Compound class:
Antibody
Comment: This therapeutic is a TNFα neutralising agent. Structurally it is a Fab' fragment of a TNFα-binding monoclonal antibody, which has polyethylene glycol (PEG) conjugated to a free cysteine residue in its hinge region (Cys227 of the heavy chain). Removing the Fc portion minimizes complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), two reactions known to cause unwanted side-effects in mAb therapies. PEGylation is used to increase the drug's half life, as Fab' fragments are normally rapidly degraded in vivo.
![]() View more information in the IUPHAR Pharmacology Education Project: certolizumab pegol |
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes (FDA (2008), EMA (2009)) |
Approved drug? | Yes. FDA (2008) | EMA (2009) |
International Nonproprietary Names ![]() |
|
INN number | INN |
8448 | certolizumab pegol |
Synonyms ![]() |
CDP870 | Cimzia® | PHA 738144 |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 242 |
Other databases | |
GtoPdb PubChem SID | 178103380 |
PubChem SID | 178103380 |
Search PubMed clinical trials | certolizumab pegol |
Search PubMed titles | certolizumab pegol |
Search PubMed titles/abstracts | certolizumab pegol |
Wikipedia | Certolizumab_pegol |